Intraoperative Infusion of Dexmedetomidine for Prevention of Postoperative Delirium in Elderly Patients
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
Postoperative delirium (POD) is a common complication, and the incidence rate is about 25% in
non-cardiac surgery. Previous studies have reported that the total incidence of neurological
POD ranged from 10% to 22%. Dexmedetomidine (DEX) is an a-2 adrenergic agonist for sedation.
This kind of drug has little effect on respiratory function, is easy to wake up and has
analgesic effect. It is a commonly used perioperative adjuvant drug. However, for elderly
patients with brain tumors, the role of DEX in POD is not clear. The purpose of this study
was to investigate the effect of DEX on POD in in elderly patients undergoing brain tumor
resections.